Glossary

📍 Quick reference: This is your pocket dictionary for the whole journey. Bookmark it and come back anytime a word stops making sense.

Every field has its own language, and biologic manufacturing has a lot of it. Here are the most important terms from this guide, in plain words, listed alphabetically so they are easy to find. Each entry is a plain-language starting point; the chapter it links to gives the full, precise picture.

Aggregate — Antibody molecules that have clumped together into bigger particles, which can trigger an unwanted immune reaction in the patient, so they are monitored and removed by polishing (see Polishing).

Aseptic — A way of working that keeps germs out, used when the product cannot be sterilized later. Note the contrast: sterilization removes or kills organisms, whereas aseptic processing keeps them out from the start because a protein medicine can't be heat- or radiation-sterilized.

At-line — A measurement made right next to the process, on a quick sample, so results come back fast.

Batch / Lot — One single run of the process; everything made together that shares the same history and quality record.

Biologic — A medicine made by living cells, usually a large, complex protein rather than a simple chemical.

Biosimilar — A near-copy of an already-approved biologic, made by a different company after the original patent ends.

Bioreactor — A controlled tank where living cells are grown to make the medicine.

Buffer — A carefully chosen salt-and-water solution that holds a steady, gentle pH (acidity) so the protein stays stable; buffers are what get swapped in and out during purification.

Capture — The first big purification step, which grabs the antibody out of a messy mixture and leaves most junk behind.

Cell bank (MCB/WCB) — Frozen, identical copies of the factory cell; the Master Cell Bank (MCB) is the original treasure, the Working Cell Bank (WCB) is the everyday stock made from it.

Cell line — A population of identical cells, all descended from one chosen cell, used to make the product.

Charge variants — Slightly modified versions of the antibody that carry a more acidic or more basic surface charge; they are a quality attribute (see CQA) that is monitored (often by charge-based methods) and kept within limits. (See Analytical and formulation.)

CHO cells — Chinese Hamster Ovary cells, the most common living factories used to make antibody medicines.

Chromatography — A purification method that separates molecules by how differently they interact with special beads inside a column: sometimes the product sticks and is later released (a mode called bind-elute), sometimes the impurities stick and the product flows through (a mode called flow-through).

Clarification — Cleaning the cloudy liquid after harvest by removing cells and debris, leaving a clear fluid that won't foul or clog the purification columns and filters downstream.

Clone / Clonality — A clone is a group of cells all descended from one single cell; clonality is the proof that they truly came from just one.

Cold chain — The unbroken chain of refrigeration that keeps the medicine cold from factory to patient.

Comparability — A structured comparison showing that the product is still the same after a change (a new site, scale, or process tweak), so it stays just as safe and effective. (See Bioprocessing overview.)

Conductivity — A measure of how much salt is in a solution; it is one of the main dials used to control when a chromatography column binds or releases the antibody. (See Capture chromatography.)

CPP (Critical Process Parameter) — A setting in the process, such as temperature, that must stay in range to keep quality right. By contrast, a CQA is a property of the product itself.

CQA (Critical Quality Attribute) — A property of the product, such as purity, that must hit its target for the medicine to be safe and to work.

DBC (Dynamic Binding Capacity) — How much antibody a unit of chromatography resin can actually grab while liquid keeps flowing through it; for modern Protein A resin this is roughly 40–80 g/L resin — that is, grams of antibody held per litre of packed beads in the column (early resins managed only 10–20). (See Capture chromatography.)

Diafiltration (DF) — Washing a protein solution by swapping its liquid for the final, gentle buffer (the salt-and-water solution that holds the protein at the right acidity) the medicine needs. (See UF/DF.)

Dissolved oxygen (DO) — The amount of oxygen in the liquid, which living cells need to breathe and stay healthy.

DOE (Design of Experiments) — A smart way of testing many settings at once to learn the best recipe with fewer experiments.

Downstream — The second half of making the medicine: purifying the antibody after the cells have made it.

Drug product (DP) — The finished medicine in its final form, such as a filled vial or syringe, ready for a patient.

Drug substance (DS) — The pure, concentrated antibody before it is put into its final vial; the active ingredient.

Elution — The step that releases the captured antibody from the column so it flows out clean, usually triggered by a pH or salt change that weakens its grip on the beads. In the standard (platform) process the eluate (the liquid that elutes off) comes off already acidic (around pH 3.8–4.0), so the very next step — a brief low-pH hold that inactivates viruses — needs only a small acid adjustment down to the target window (about pH 3.3–3.6), not a separate acidification step. (See Capture chromatography.)

EMA (European Medicines Agency) — The agency that reviews and approves medicines for the European Union, the European counterpart to the FDA.

Endotoxin — A toxic substance from certain bacteria that can cause fever and must be kept extremely low (below the official limits set in the pharmacopeia, the legally recognized reference book of medicine-quality standards, such as the US or European Pharmacopeia).

Excipient — A helper ingredient, such as sugar or salt, added to keep the protein stable and comfortable.

FDA (Food and Drug Administration) — The United States agency that reviews and approves medicines and inspects the factories that make them; the EMA is its European counterpart.

Fed-batch — The standard way to grow cells, feeding them extra nutrients over time in one big tank, then harvesting once.

Fill-finish — The final stage where the pure medicine is filled into vials or syringes, sealed, and inspected.

Formulation — The recipe of the final liquid, choosing the right excipients so the medicine stays stable and safe to inject.

Glycan — A sugar chain attached to the antibody that strongly affects how well and how safely it works.

GMP / cGMP — Good Manufacturing Practice, the strict, legally required rules for making medicine safely and consistently.

Harvest — Collecting the medicine-rich liquid from the bioreactor once the cells have done their job.

Host cell protein (HCP) — Leftover proteins from the factory cells that can be immunogenic (can trigger an unwanted immune reaction in the patient), so they are tracked in parts per million (ppm) and cleaned down to very low levels in the final medicine. (See Analytical and formulation.)

ICH — The International Council for Harmonisation, which writes the globally agreed guidelines regulators follow; its "Q-series" pairs each code with a quality topic — Q5 (biotech product quality, including viral safety), Q6B (specifications and acceptance limits), Q8 (pharmaceutical development), Q9 (quality risk management), and Q10 (quality systems).

IND / BLA — An IND (Investigational New Drug) is the application to start human testing; a BLA (Biologics License Application) is the request to sell the approved medicine.

LRV (Log Reduction Value) — A score for how many viruses a step removes or kills, counted in powers of ten: 1 log is a 10x reduction, 2 logs 100x, and so on; a virus filter typically delivers around 3–4 logs, and the cleared steps are added up to prove overall safety. (See Viral filtration.)

Lyophilization — Freeze-drying the medicine into a stable powder that is mixed with liquid again before use.

Monoclonal antibody (mAb) — A single, precisely targeted antibody made in huge identical copies to treat disease.

PAT (Process Analytical Technology) — Tools that measure the process as it runs, so problems are caught and fixed in real time.

Perfusion — A modern way to grow cells where fresh food flows in and product flows out continuously, keeping cells productive for weeks.

Polishing — The final purification steps that remove the last tiny impurities, such as aggregates.

Potency — A measure of how strongly the medicine does its job, confirming the product truly works.

Process development — The lab work of inventing and perfecting the recipe before making medicine at full scale.

Protein A — A special material that grabs antibodies very selectively by latching onto the Fc stem (the antibody's stable "tail" region, nearly identical and shared across almost all antibodies) that nearly all antibodies share, which is why one resin works as a platform across many different molecules. (See Capture chromatography.)

QA (Quality Assurance) — The team and system that build quality into every step and decide whether a batch can be released.

QC (Quality Control) — The lab that tests samples to confirm the product meets its quality targets.

Resin / Column — The resin is the tiny purifying beads; the column is the tube that holds them so liquid can flow through.

Seed train — Growing the cells in a series of ever-larger flasks and tanks to build enough of them for the big bioreactor.

Serialization — Giving each pack a unique code so it can be tracked and proven genuine, fighting counterfeits.

Single-use — Equipment made of sterile plastic, used once and thrown away, which avoids cleaning and cross-contamination.

Specification — The agreed list of tests, with pass/fail limits, that a batch must meet before it can be released; it is the formal definition of "good enough to ship."

Stability — How well the medicine holds up over time and under stress (heat, light, freezing); stability studies set the shelf life and storage conditions.

Sterile filtration — Pushing the liquid through a fine (0.2 micron) filter that removes bacteria, making the product germ-free; the filter is integrity-tested to prove it held. (See Analytical and formulation.)

Tech transfer — Handing the recipe and know-how from the lab to the factory so it can be made at large scale.

Titer — How much antibody the cells make per liter of liquid, measured in grams per litre (g/L); a modern fed-batch run reaches roughly 2–8 g/L (high-performing platforms reaching ~10 g/L), and higher titer means a more productive process. (See Bioprocessing overview.)

Upstream — The first half of making the medicine: growing the cells so they produce the antibody.

UF/DF — Ultrafiltration and Diafiltration, the step that concentrates the antibody and swaps in the final buffer.

Viable cell density (VCD) — How many living cells are packed into each millilitre of culture; it is a key gauge of bioreactor health, peaking around 5–20 million cells/mL in fed-batch (and far higher, roughly 50–100 million cells/mL, in perfusion). (See Process development.)

Viral clearance — The overall ability of the process to remove or kill viruses, proven across several orthogonal steps (steps that work by different mechanisms, so a virus surviving one is caught by another) and added up as an LRV total.

Viral filtration — Pushing the liquid through an ultra-fine filter that physically traps viruses.

Viral inactivation — A step, often a short time at low pH, that destroys fragile enveloped viruses (ones wrapped in a soft fatty outer coat that low pH breaks apart), which is why a second, size-based step (viral filtration) is still needed for the tough non-enveloped ones (which have only a hard protein shell and survive low pH). (See Viral inactivation.)

If a term here still feels fuzzy, follow it back into the chapter where it lives, and it will make far more sense in context.